Chymase Angiotensin-(1-12) Axis In Hypertensive Disease
Launched by TRINITY HYPERTENSION & METABOLIC RESEARCH INSTITUTE · Dec 6, 2022
Trial Information
Current as of January 13, 2025
Unknown status
Keywords
ClinConnect Summary
This clinical trial is studying a specific substance in the blood called Angiotensin-(1-12) and how it relates to high blood pressure, also known as hypertension. The researchers want to see if this substance is present in people with untreated hypertension and how a medication called Lisinopril, taken daily for four weeks, can lower blood pressure. Lisinopril is commonly used to help manage high blood pressure.
To be eligible for the study, participants must be between 40 and 75 years old, have not been on any blood pressure medications for at least six months, and have specific levels of high blood pressure. Participants will need to attend several study visits and provide consent to take part in the research. This trial is currently looking for volunteers, and it is important for both men and women to meet certain health criteria before joining. If you decide to participate, you can expect regular check-ins and monitoring of your blood pressure and health throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Capable of reading, comprehending the consent process and providing written informed consent to participate in the study
- • 2. Subject willing to comply with all study visits/procedures and be available for the duration of the study
- • 3. Male or female 40 years of age to 75 years of age
- • 4. Male and female subjects naive to anti-hypertensive medications or receiving no anti-hypertensive medication for at least 6 months prior to visit 1
- • 5. Stage I-II hypertension defined as a baseline mean seated cuff Diastolic blood pressure of equal/over 90 mm Hg and equal/less 109 mm Hg and/or Systolic blood pressure equal/over 140 mm Hg and equal/less 179 mm Hg on visit 1
- 6. Women may be enrolled if all three of the following criteria are met:
- • Have a negative urine pregnancy test at visit 1, for females of childbearing potential Are not breastfeeding Do not plan to become pregnant during the study And if one of the following three criteria is met Have had a hysterectomy or tubal ligation at least six months prior to signing the informed consent form Have been postmenopausal for at least one year Are of childbearing potential and will practice one of the following methods of birth control though out the study: oral, patch, injectable, or implantable hormone contraception, intrauterine device, diaphragm plus spermicide or female condom plus spermicide. Abstinence, partner's vasectomy are not acceptable methods of contraception
- Exclusion Criteria:
- • -
Trial Officials
Henry Punzi, MD
Principal Investigator
Trinity Hypertension & Metabolic Researach Institute
About Trinity Hypertension & Metabolic Research Institute
Trinity Hypertension & Metabolic Research Institute is a leading clinical research organization dedicated to advancing the understanding and treatment of hypertension and metabolic disorders. With a commitment to innovative research and patient-centered care, the institute conducts rigorous clinical trials aimed at developing effective therapies and improving health outcomes for individuals affected by these conditions. Leveraging a multidisciplinary team of experts, cutting-edge technology, and a collaborative approach, Trinity strives to contribute significantly to the scientific community and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Carrollton, Texas, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials